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Objective: We performed a retrospective study evaluating the effect on survival of different sites of microscopic
residual disease at the bronchial resection margin after surgical intervention for non–small cell lung cancer.
Methods: Survival of patients with different sites of residual disease was compared with survival of patients with
curative resections, taking the pathologic TNM stage of the tumor into consideration.
Results: There was a trend for patients with stage I and II non–small cell lung cancer with residual disease limited
to the epithelium and with peribronchial invasion to behave like patients with complete resections (61% and 41%
five-year survival for stage I and II disease, respectively). This contrasts with patients with submucosal invasion
and lymphatic infiltration, among whom there were no survivors at 5 years. There was no difference in survival
between curative resections and residual disease of any type when the tumor was stage III or IV.
Conclusions: In patients with stage I and II disease, when residual disease consists of submucosal invasion or
lymphatic infiltration, specific and aggressive treatments to clear residual margins might be contemplated because
of their possible adverse effect on survival. This contrasts with patients with stage III and IV disease, in whom
survival is more related to the stage of the primary tumor than to residual disease.
General Thoracic Surgery Collaud et alResection of localized non–small cell lung cancer (NSCLC)
is considered complete when all margins involved (ie, bron-
chial, vascular, and soft tissue) are confirmed to be free of
tumor by the pathologist. Such a finding is termed R0 by
the American Joint Committee on Cancer.1 Although mac-
roscopic residues (R2) are clearly associated with grim prog-
noses,2 the issue of microscopic residues (R1) is not so clear,
and management is still controversial.
Whereas initial studies of R1 resection were obscured by
a lack of precise surgical staging, the most recent studies
have correlated results with pathologic extent of disease.3-5
Furthermore, since 1959, it now appears that prognosis
might differ according to the pattern of residual disease at
the bronchial resection margin.5-7
The aim of this study is to establish the survival of patients
undergoing operations in a single center according to differ-
ent patterns of residual disease at the bronchial resection
margin with adjustment to pathologic staging.
MATERIALS AND METHODS
The clinical records of 584 consecutive patients who underwent surgical
intervention for NSCLC in our center between January 1992 and December
2000 were reviewed. Follow-up ended December 31, 2005. All patients un-
derwent thoracotomy with lobectomy, bilobectomy, or pneumonectomy
and mediastinal lymph node dissection. Patients with wedge resections
were excluded. The staging system was the International Staging System
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the hospital’s ethics committee, and informed consent was obtained from
each surviving patient.
Survival curves were calculated by using Kaplan–Meier and life table
methods, and R1 types were compared by using the Mantel–Cox log-rank
test after stratification for stage (stage I and II vs stage III and IV).
The study comprises 37 patients with microscopic residual disease at the
bronchial margin (33 men and 4 women; age 33–75 years; median age, 63
years). Patients with carcinoid tumors (4 patients) or having had induction
treatment (1 patient with chemotherapy) were excluded. Pulmonary resections
performed were lobectomies in 20 patients (including 4 sleeve resections on the
right upper lobe and 4 extended lobectomies, 2 to the thoracic wall and 2 to the
adjacent lobe through a wedge resection), bilobectomies in 6 patients, and
pneumonectomies in 11 patients (including 2 extended to the thoracic wall).
After pathology review of tumor slides, patients were classified into 4
different types of R1 according to the exact anatomic site of residual disease
(Figure 1): (1) disease limited to the epithelium, including carcinoma in situ
R1(is) and dysplasia; (2) submucosal invasion; (3) peribronchial invasion;
and (4) lymphatic infiltration.
Patients and their characteristics are summarized in Table 1. Because sur-
vival is known to be correlated with pathologic TNM stage of the primary
tumor,9 we compared the different types of R1 after stratification to patho-
logic staging. Patients were then allocated to expectedly favorable and un-
favorable outcome groups composed of pathologic stage I and II disease for
the first group and stage IIIA, IIIB, and IV disease for the second group,
respectively.
We thus identified epithelial limited disease in 5 patients (dysplasia in 2
patients and carcinoma in situ in 3 patients), submucosal invasion in 7 pa-
tients, peribronchial invasion in 15 patients, and lymphatic infiltration in
10 patients. Histopathologic examination identified squamous cell carci-
noma in 22 patients, adenocarcinoma in 11 patients, and large cell carci-
noma in 4 patients.
Thirteen patients received radiotherapy postoperatively, 6 of whom re-
ceived it after 3 or 4 cycles of platin-based chemotherapy. Radiotherapy
was started 30 to 156 days after surgical intervention (median, 40 days)
and was aimed at the mediastinum and usually the bronchial stump; doses
applied ranged from 12 to 80 Gy (median, 60 Gy) in 6 to 48 daily fractions
(median, 31 Gy).
The site of first recurrence was termed local when it was intrathoracic
and distant when it was extrathoracic. The term not available was used
for patients who did not have extensive research on the site of relapse.rgery c March 2009
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Follow-up for surviving patients ranged from 5 to 12 years. Twenty-eight
patients died during the follow-up, including 6 within the first month of
postoperative complication. Postoperative complications included infection
in 4 patients (pulmonary in 3 patients and chest wall phlegmon in 1 patient)
and heart rhythm disorders in 1 patient; 1 patient died a few hours after
pneumonectomy of rupture of the pulmonary artery stump.
It should be kept in mind that given the small sizes of the 4 subgroups
considered (between 5 and 15 patients in each), findings observed should
be interpreted with some caution and compared with larger series of
patients.
Disease Limited to Epithelium
Two types of lesions were considered in this subgroup: dysplasia and
carcinoma in situ. Dysplasia refers to lesions with cellular abnormalities
within the columnar epithelium of the bronchus that do not reach the full
thickness of the epithelium, and carcinoma in situ refers to proliferation
of neoplastic cells in the full thickness of the epithelium, with intact base-
ment membrane and without invasion of surrounding tissues.
Of the 5 patients in this group, all had early-stage NSCLC and did not
receive any adjuvant treatment. Four are alive, with survivals varying
from 69 to 142 months.
Submucosal Invasion
Of the 7 patients with submucosal invasion, 5 had early-stage NSCLC,
and 2 had locoregionally advanced tumors. Three patients had radiotherapy
as consolidation therapy after pulmonary resections. One patient was lost to
follow-up after 59 months and was censored at that time.
Peribronchial Invasion
Of the 15 patients with peribronchial invasion, 7 had early-stage
NSCLC, 6 had locoregionally advanced disease, and 2 had metastatic dis-
ease. Both patients with stage IV disease were given diagnoses after surgical
intervention: each lesion (a retro-orbital lesion and a skin metastasis) was
discovered after surgical intervention but was already present before. In 5
cases tumors relapsed outside the thorax and were treated with radiotherapy.
One patient relapsed locally and was treated with chemotherapy.
Lymphatic Infiltration
Of the 10 patients in this subgroup, 7 had locoregionally advanced
tumors. Despite adjuvant combined radiochemotherapy in 5 patients, recur-
rences occurred both inside and outside the thorax, with poor outcomes.
RESULTS
There is a marginally nonsignificant difference in survival
between the 4 types of R1 disease after stratification for path-
ologic staging (P ¼ .063) compared with a P value of .007
when no stratification for staging is done.
Figures 2 and 3 detail survivals for each pattern of R1 dis-
ease and compare them with survivals achieved by patients
with R0 disease, as provided by the Geneva Cancer Registry.
Survivals for expectedly favorable, expectedly unfavorable,
and R0 groups at 1, 2, and 5 years (with 95% confidence in-
tervals) are summarized in Table 2.The Journal of Thoracic and CIt appears that within the so-called favorable group (Fig-
ure 2 and Table 2), 5-year survival achieved by patients
with disease limited to the epithelium (n ¼ 5 [100%]) and
peribronchial invasion (n ¼ 7 [43%]) is somewhat better
than the 61% and 41% (Figure 2 and Table 2) achieved
by control patients with stage I and II disease. In contrast,
patients with submucosal invasion (n ¼ 5) and lymphatic
infiltration (n ¼ 3) fared much worse than control patients.
As for the unfavorable group, 5-year survival achieved by
patients with any pattern of R1 disease is similar to survival
of patients with R0 disease (Figure 3 and Table 2).
DISCUSSION
Risk Factors for Positive Bronchial Resection
Margins
Positive bronchial resection margins are reported after
1.6% to 14.7%3,7 of standard lung resections, with a some-
what higher incidence for sleeve lobectomies (6.9% to
13%).10,11 In the present study, when excluding patients
with dysplasia (n ¼ 3), as most authors do, we found 35
(6%) cases of residual disease in a series of 584 consecutive
lung resections (including 4 sleeve resections on the right
upper lobe). The probability of residual disease is estimated
to equal 100% when the bronchial margin is less than 1 mm
from the tumor, 30% when the distance is 2 to 5 mm, and
zero when the distance is more than 20 mm.12 It seems nei-
ther preoperative medical imaging and endoscopy nor intra-
operative frozen sections of the resection margin suffice to
prevent incomplete resections, partly because of the high
false-negative rate of frozen sections, which is reported to
be as high as 41.7%.3 In this setting frozen sections should
be limited to bronchoplastic resections and to elective situa-
tions in which the bronchial section is close to the tumor.
FIGURE 1. The 4 sites of residual tumor at the bronchial resection margin
are disease limited to the epithelium (1), submucosal invasion (2), peribron-
chial invasion (3), and lymphatic infiltration (4).ardiovascular Surgery c Volume 137, Number 3 623
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Patient
no.
pTNM
staging* Histology
Adjuvant
treatment
Site of first
recurrence
Delay from
operation (mo) Treatment
Survivaly
(mo)
Disease limited
to epithelium
1 I (is) squ 0 L 53 re-opþ rt 69þ
2 I (is) squ 0 L 61 0 63
3 II (is) squ 0 0 142þ
4 II (d) squ 0 0 122þ
5 II (d) squ 0 0 133þ
Submucosal invasion 6 I squ 0 NA 4
7 I squ rt LþD 7 ch 8
8 I squ rt NA 33
9 I squ 0 L 16 rt 28
10 II squ rt L 26 re-op 29
11 IIIA adc 0 0 59þ*
12 IIIA squ 0 0 1
Peribronchial invasion 13 I adc 0 0 0
14 I lac 0 L 21 ch 36
15 I squ 0 0 91þ
16 I lac rt 0 132þ
17 I squ rt NA 47
18 II adc 0 D 15 rt 17
19 II squ 0 0 67þ
20 IIIA lac rtþch 0 72þ
21 IIIA squ 0 0 0
22 IIIA squ ch D 11 rt 11
23 IIIA squ 0 0 0
24 IIIB squ rt D 10 rt 26
25 IIIB squ 0 0 1
26 IV squ 0 D 0 rt 3
27 IV adc 0 D 1 rt 5
Lymphatic infiltration 28 I squ rt NA 19
29 I squ 0 LþD 4 0 4
30 II adc rtþch D 11 rt 22
31 IIIA adc rtþch L 5 0 9
32 IIIA adc 0 0 0
33 IIIA adc rtþch LþD 6 rt 6
34 IIIA lac NA LþD 5 0 19
35 IIIB adc rtþch L 3 rt 14
36 IIIB adc rtþch L 24 0 42
37 IIIB adc 0 D 1
squ, Squamous cell carcinoma; L, local; re-op, reoperation; rt, radiotherapy; NA, not available; D, distant; ch, chemotherapy; adc, adenocarcinoma; lac, large cell carcinoma. *Type
of disease limited to the mucosa: is, carcinoma in situ; d, dysplasia. yþ, Alive at the end of follow-up;þ*, lost to follow-up after 59 months.Survival of the Different Types of Residual Disease at
the Bronchial Resection Margin
Favorable group (stage I and II disease). Diseases lim-
ited to the epithelium form a heterogenous group, including
dysplasia and carcinoma in situ. Such lesions can be found at
the bronchial margin but also elsewhere along the bronchial
airway; carcinoma in situ, for instance, has been reported in
as much as 9.3% of lungs resected for carcinoma (by using
fluorescence bronchoscopy).13
In the present study disease limited to the epithelium at the
bronchial resection margin was found to be associated with
a 100% survival at 5 years but decreased to 80% (95% con-624 The Journal of Thoracic and Cardiovascular Sufidence interval, 38% to 96%) 3 months later, which is
slightly better than in Dutch5 and British7 series (58% and
70%, respectively). Such a finding, which has already
been shown in a recent review,14 likens this subgroup to pa-
tients with R0 disease. One explanation for such favorable
outcomes is that these lesions are usually found incidentally
at the time of pathologic examination and do not represent
true residual disease at the bronchial resection margin. Al-
though these are preinvasive lesions (the pathologic se-
quence goes from hyperplasia to metaplasia to dysplasia to
carcinoma in situ and finally to invasive cancer15), they do
not influence survival. Accordingly, they should probablyrgery c March 2009
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at the bronchial margin.
Although clearly more common in advanced stages, lym-
phatic infiltration was associated with early stages in 3 of 10
patients; even then, survival was dismal (no patient survived
2 years). This might express early systemic dissemination
and argue for chemotherapy (for systemic treatment) and
mediastinal radiotherapy (for local control) rather than for
reoperation.
The definition of different types of R1 resection in terms
of the site of microscopic residual disease is not uniform in
the literature.14 Submucosal and peribronchial invasions are
sometimes studied separately16 or as a whole.5 Their behav-
ior was somewhat different in the present series. Peribron-
chial invasion (n ¼ 7) had a 43% (95% confidence
interval, 16% to 75%) survival at 5 years (which is similar
to our stage II R0 group), whereas survival with submucosal
invasion (n ¼ 5) was far worse than that seen in the control
group (no survivors at 5 years vs 61% for patients with stage
I R0 disease and 41% for patients with stage II R0 disease,
respectively). The reason why these somewhat comparable
residual tumors do not have the same fate is all but clear be-
cause several factors should have favored the submucosal
subgroup instead: (1) stage I tumors prevail (4/5 early stages
vs 5/7 in the peribronchial subgroup); (2) squamous cell his-
tology is dominant (5/5 vs 3/7, respectively); and (3) absence
of postoperative death (vs 1 in the peribronchial subgroup).
No doubt a study with larger figures could help assess these
findings.
In view of these contrasting behaviors, it is tempting to
propose 2 different therapeutic approaches: peribronchial in-
FIGURE 2. Survival for the different sites of residual disease in the expect-
edly favorable group.The Journal of Thoracic and Cvasion should be treated according to the stage of the pri-
mary tumor without taking into account R1 disease. On
the contrary, the handling of cases with submucosal invasion
is unclear. Adjuvant radiotherapy has been suggested by
some in view of relatively good survival rates, decrease in
the number of local recurrences, or both.16-18 Others, how-
ever, see no benefit to radiotherapy,5,19 as in our experience.
Reoperation could then be the best option to clear bronchial
TABLE 2. Overall survival at 1, 2, and 5 years
Overall survival
(95% confidence interval)
N 1 y 2 y 5 y
Favorable group
Geneva Tumor
Registry stage I
218 89 (85–93) 82 (76–88) 61 (55–67)
Geneva Tumor
Registry stage II
77 78 (68–88) 65 (55–75) 41 (29–53)
Disease limited to
epithelium
5 100 100 100
Submucosal invasion 5 60 (23–88) 60 (23–88) 0
Peribronchial invasion 7 86 (49–97) 71 (36–92) 43 (16–75)
Lymphatic infiltration 3 67 (21–94) 0 0
Unfavorable group
Geneva Tumor
Registry stage IIIA
71 70 (60–80) 50 (38–62)
Geneva Tumor
Registry stage IIIB
17 53 (29–77) 41 (17–65)
Geneva Tumor
Registry stage IV
91 34 (24–44) 18 (10–26)
Submucosal invasion 2 50 (10–90) 50 (10–90)
Peribronchial invasion 8 25 (7–59) 12 (2–47)
Lymphatic infiltration 7 43 (16–75) 14 (3–51)
The life-table method was used for the Geneva Tumor Registry, and the Kaplan–Meier
method was used for residual tumor groups.
FIGURE 3. Survival for the different sites of residual disease in the expect-
edly unfavorable group.ardiovascular Surgery c Volume 137, Number 3 625
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been suggested.17
Unfavorable group (stage III and IV disease). Patients
with R0 disease and the 3 subtypes of R1 disease behave
similarly, whatever the exact subtype of residual disease.
For patients with advanced disease, the presence of residual
disease at the bronchial resection margin is clearly less deci-
sive than N2 and obviously M1 status and thus eliminates
the necessity of clearing the bronchial margin with a reoper-
ation. Radiotherapy (as indicated in patients with R0 disease
with N2 status) combined with chemotherapy could then be
the treatment of choice despite the absence of any study sup-
porting adjuvant chemotherapy after R1 resections.
Residual disease at the bronchial margin is a rare finding.
Comparing patients with similar stages and similar sites of re-
sidual disease will invariably result in small samples. In such
a setting, results and therapeutic suggestions should thus be
interpreted with caution. The present study provides a simple
microscopic classification for residual bronchial disease.
Taking into account the stage of the primary tumor and the
site of the microscopic residual disease leads to interesting
prognostic implications. Points of interest, for instance,
could include the effect of radiotherapy and reoperation.
This deserves further assessment in a larger, prospective,
and ideally randomized study.
We thank Mrs Bernadette Mermillod for her help in the statisti-
cal analysis of the data.
References
1. American Joint Committee on Cancer (AJCC). AJCC cancer staging handbook.
6th ed. New York: Springer; 2002.
2. Pitz CCM, Brutel de la Rivie`re A, Elbers HRJ, Westermann CJJ, Van den
Bosch JM. Results of resection of T3 non-small cell lung cancer invading the
mediastinum or main bronchus. Ann Thorac Surg. 1996;62:1016-20.
3. Kaiser LR, Fleshner P, Keller S, Martini N. Significance of extramucosal residual
tumor at the bronchial resection margin. Ann Thorac Surg. 1989;47:265-9.626 The Journal of Thoracic and Cardiovascular Sur4. Liewald F, Hatz R, Dienemann H, Sunder-Plassmann L. Importance of micro-
scopic residual disease at the bronchial margin after resection for non-small cell
carcinoma of the lung. J Thorac Cardiovasc Surg. 1992;104:408-12.
5. Snijder RJ, Brutel de la Rivie`re A, Helbers HJ, van den Bosch JM. Survival in
resected stage I lung cancer with residual at the bronchial resection margin.
Ann Thorac Surg. 1998;65:212-6.
6. Cotton RE. The bronchial spread of lung cancer. Br J Dis Chest. 1959;53:142-50.
7. Soorae AS, Stevenson HM. Survival with residual tumor on the bronchial margin
after resection for bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1979;78:
175-80.
8. Moutain CF. Revisions in the international system for staging lung cancer. Chest.
1997;111:1710-7.
9. Lequaglie C, Conti B, Brega Massone P, Giudice G. Unsuspected residual disease
at the resection margin after surgery for lung cancer: fate of patients after long-
term follow-up. Eur J Cardiothorac Surg. 2003;23:229-32.
10. Van Schil PE, Brutel de la Rivie`re A, Knaepen PJ, van Swieten HA, Defauw JJ,
van den Bosch JM. TNM staging and long term follow-up after sleeve resection
for bronchogenic tumors. Ann Thorac Surg. 1991;52:1096-101.
11. Mehran RJ, Deslauriers J, Piraux M, Beaulieu M, Guimont C, Brisson J. Survival
related to nodal status after sleeve resection for lung cancer. J Thorac Cardiovasc
Surg. 1994;107:576-83.
12. Kayser K, Anyanwu E, Vogt-Moykopf I. Tumor presence at resection boundaries
and lymph-node metastasis in bronchial carcinoma patients. Thorac Cardiovasc
Surg. 1993;41:308-11.
13. Pierard P, Vermylen P, Bosschaerts T, Roufosse C, Berghmans T, Sculier JP, et al.
Synchronous roentgenographically occult lung carcinoma in patients with resect-
able primary lung cancer. Chest. 2000;117:779-85.
14. Wind J, Smit EJ, Senan S, Eerenberg J-P. Residual disease at the bronchial stump
after curative resection for lung cancer. Eur J Cardiothorac Surg. 2007;32:
29-34.
15. Ruffini E, Bongiovanni M, Cavallo A, Filosso PL, Giobbe R, Mancuso M, et al.
The significance of associated pre-invasive lesions in patients resected for primary
lung neoplasms. Eur J Cardiothorac Surg. 2004;26:165-72.
16. Massard G, Doddoli C, Gasser B, Ducrocq X, Kessler R, Schumacher C, et al.
Prognostic implications of a positive bronchial resection margin. Eur J Cardio-
thorac Surg. 2000;17:557-65.
17. Ghiribelli C, Voltolini L, Paladini P, Luzzi L, Di Bisceglie M, Gotti G. Treatment
and survival after lung resection for non-small cell lung cancer in patients with
microscopic residual disease at the bronchial stump. Eur J Cardiothorac Surg.
1999;16:555-9.
18. Gebitekin C, Gupta NK, Satur CMR, Olgac G, Martin PG, Saunders NR, et al.
Fate of patients with residual tumour at the bronchial resection margin. Eur J Car-
diothorac Surg. 1994;8:339-44.
19. Lacasse Y, Bucher HC, Wong E, Griffith L, Walter S, Ginsberg RJ, et al. Incom-
plete resection in non-small cell lung cancer: need for a new definition. Ann
Thorac Surg. 1998;65:220-6.gery c March 2009
